{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-081941","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.453962+00:00","generated_at":"2026-06-09T03:02:28.685654+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Jasper appoints Thomas G. Wiggans as Chairperson; William Lis to retire in Dec 2023","bullets":["Thomas G. Wiggans joins Board as Class II director and Chairperson effective Nov 1, 2023.","Wiggans, 71, is former CEO/founder of Dermira (acquired by Lilly), ex-CEO of Pardes Biosciences.","Wiggans receives option to purchase 110,000 shares, vesting over 4 years; larger than standard director grant.","William Lis steps down as Chairperson immediately, will resign from Board on Dec 14, 2023 (no disagreement).","Company focuses on briquilimab for mast cell diseases and LR-MDS; initial CSU study launching."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-081941","json":"https://secwatch.observer/filing/0001213900-23-081941.json","markdown":"https://secwatch.observer/filing/0001213900-23-081941.md","text":"https://secwatch.observer/filing/0001213900-23-081941.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023081941/0001213900-23-081941-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023081941/ea187564-8k_jasper.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T03:02:28.685654+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8e340d5a24","claim":"Thomas G. Wiggans was appointed as Chairperson of the Board at Jasper Therapeutics, Inc..","evidence_excerpt":"Effective November 1, 2023, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) appointed Thomas G. Wiggans as a Class II director of the Company. Mr. Wiggans was also appointed to serve as Chairperson of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023081941/0001213900-23-081941-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairperson of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}